Patrick A. Baeuerle Explained

Patrick A. Baeuerle
Birth Name:Patrick Alexander Baeuerle
Birth Date:24 November 1957
Birth Place:Friedrichshafen, West Germany
Occupation:Molecular biologist, Immunologist, Entrepreneur and professor
Years Active:1986-present

Patrick Baeuerle (born 24 November 1957) is a German-based molecular biologist, immunologist, professor and a biopharmaceutical entrepreneur. Baeuerle is known for his work on tyrosine sulfation of proteins,[1] transcription factor NF-kappaB,[2] and the development of bispecific T-cell engaging antibodies for therapy of cancer.[3]

Education

Baeuerle earned his diploma in biology from University of Konstanz, Germany. He received his Ph.D. in biochemistry summa cum laude, from the Ludwig Maximilian University of Munich. His postdoctoral training was with the Nobel Laureate David Baltimore at the Whitehead Institute at Massachusetts Institute of Technology, Cambridge, MA.[4] [5]

Career

After his post-doctorate, Baeuerle led a research group at Gene Center in Martinsried, Germany. In 1993, he became the professor of molecular biology, and was and the chairman at the medical faculty of Freiburg University, Germany.[6]

Between 1996 and 2015, he served as head of drug discovery at Tularik Inc.,[7] [8] as chief scientific officer at Micromet Inc.,[9] [10] and as a vice president research for Amgen Inc.[11] in Munich, Germany.

Baeuerle is the co-founder of the companies, iOmx AG, Harpoon Inc,[12] TCR2 Inc, Maverick Inc, and Cullinan LLC. He is one of the Managing directors at MPM capital, which is a Cambridge-based venture capital firm.[11] [13]

Research Activities

Tyrosine Sulfation

In 1987, Baeuerle showed that tyrosine sulfation is a frequent modification of secretory proteins that is added in the trans-Golgi compartment.[14]

Transcription factor NF-kappaB

Baeuerle deciphered the canonical pathway by which transcription factor NF-kappaB is activated and first described inhibitory subunit I-kappaB and the p65/RelA subunit.[2] [15] Baeuerle is said to be one of the inventors of the controversial NF-kappaB.[16] [17] He along with his team showed that NF-kappaB is an oxidative stress-responsive transcription factor and described a functional role of NF-kappaB in the nervous system.[18] [19]

Cancer Therapy

Baeuerle lead the development of BiTE antibody Blincyto® (blinatumomab; AMG 103)[20] which is approved by the US FDA for treatment of relapsed/refractory acute lymphoblastic leukemia.[21] [22] He has invented various antibody-based constructs that are designed to engage cytotoxic T cells for lysis of cancer cells.[23]

External links

  1. University of Munich
  2. Micromet, Inc.
  3. University of Konstanz
  4. Max-Planck Institute of Molecular Cell Biology and Genetics
  5. Max-Planck Institute for Neurobiology
  6. EMBL
  7. Whitehead Institute
  8. GeneCentre
  9. University of Freiburg
  10. NF-kappa B (516) patent

Notes and References

  1. Baeuerle . P A . Huttner . W B . Tyrosine sulfation is a trans-Golgi-specific protein modification. . Journal of Cell Biology . 1 December 1987 . 105 . 6 . 2655–2664 . 10.1083/jcb.105.6.2655 . 2114704 . 3121635 .
  2. Baeuerle . P A . Henkel . T . Function and Activation of NF-kappaB in the Immune System . Annual Review of Immunology . April 1994 . 12 . 1 . 141–179 . 10.1146/annurev.iy.12.040194.001041 . 8011280 .
  3. Baeuerle . Patrick A. . Reinhardt . Carsten . Bispecific T-Cell Engaging Antibodies for Cancer Therapy . Cancer Research . 15 June 2009 . 69 . 12 . 4941–4944 . 10.1158/0008-5472.CAN-09-0547 . 19509221 .
  4. 1989-03-01. Patrick A. Baeuerle, David Baltimore, Whitehead Institute For Biomedical Research. WO. 1989008147. ACTIVITION OF NF-kB PRECURSOR.
  5. Baeuerle . Patrick A. . Baltimore . David . Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-κB transcription factor . Cell . April 1988 . 53 . 2 . 211–217 . 10.1016/0092-8674(88)90382-0 . 3129195 . 24771542 .
  6. News: Hall . Stephen S. . Success Is Like a Drug . The New York Times . 23 November 1997 .
  7. Web site: Two Distinct Career Paths Offer Clear Choices. The Scientist. 2017-10-04.
  8. Web site: Reinventing the Antibody. The Scientist. 2017-10-04.
  9. News: Perkel . Jeffrey . New Lymphoma Drug Shows Promise . Washington Post . 14 August 2008 .
  10. News: TCR2 Therapeutics Unveils New Cancer Therapy Approach and $44.5M Round Xconomy. 2016-12-08. Xconomy. 2017-10-04. English.
  11. Web site: Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platform. endpts.com. English. 2017-10-04.
  12. News: Gormley . Brian . Harpoon Therapeutics Snares $45 Million Series B for Prostate Cancer Treatment . WSJ . 25 May 2017 .
  13. News: MPM Names Drug Developer Patrick Baeuerle Managing Director . Wall Street Journal . 13 March 2015 .
  14. Web site: Tyrosine sulfation of yolk proteins 1, 2, and 3 in Drosophila melanogaster (PDF Download Available). ResearchGate. en. 2017-10-04.
  15. Baeuerle . Patrick A. . Baltimore . David . IκB: a Specific Inhibitor of the NF-κB Transcription Factor . Science . 28 October 1988 . 242 . 4878 . 540–546 . . 10.1126/science.3140380 . 3140380 . 1988Sci...242..540B .
  16. Nuclear factors associated with transcriptional regulation. Jun 25, 2002. Baltimore. Sen. Sharp. David. Ranjan. Phillip A.. US. 6410516.
  17. Web site: Espacenet - Bibliographic data. worldwide.espacenet.com. en. 2017-10-04.
  18. Web site: Patrick A. Baeuerle - Google Scholar Citations. scholar.google.de. 2017-10-04.
  19. Schreck . Ralf . Albermann . Kaj . Baeuerle . Patrick A. . Nuclear Factor Kb: An Oxidative Stress-Responsive Transcription Factor of Eukaryotic Cells (A Review) . Free Radical Research Communications . January 1992 . 17 . 4 . 221–237 . 10.3109/10715769209079515 . 1473734 .
  20. Baeuerle . Patrick A. . Kufer . Peter . Bargou . Ralf . BiTE: Teaching antibodies to engage T-cells for cancer therapy . Current Opinion in Molecular Therapeutics . February 2009 . 11 . 1 . 22–30 . 19169956 .
  21. News: Swaminathan . Nikhil . Antibody Drug Unleashes Tumor-Killer T Cells . Scientific American . 15 August 2008 .
  22. News: Highfield . Roger . Patients 'free from cancer' after immune-boost treatment . The Telegraph . 14 August 2008 .
  23. Baeuerle . Patrick A. . Reinhardt . Carsten . Bispecific T-Cell Engaging Antibodies for Cancer Therapy . Cancer Research . 15 June 2009 . 69 . 12 . 4941–4944 . 10.1158/0008-5472.CAN-09-0547 . 19509221 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Patrick A. Baeuerle".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.